Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Communication to the Editor
New Cancer Immunotherapy Using Autologous Lymphocytes Activated with Trastuzumab
Shinichirou NakagawaYusuke MatsuokaHideaki IchiharaHitoji YoshidaKenshi YoshidaRyuichi Ueoka
Author information

2012 Volume 35 Issue 8 Pages 1213-1215


It is well known that trastuzumab (TTZ) is molecular target drug for breast cancer overexpressing human epidermal growth factor receptor 2 (HER2). Novel immunotherapy by human peripheral blood mononuclear cells (PBMCs) activated with TTZ were examined. Proliferation of lymphocytes after adding of TTZ was obtained. Furthermore, lymphocytes activated with TTZ inhibited growth of breast cancer cells in vitro. It is noteworthy that remarkably high cellular cytotoxicity in lymphocytes activated with TTZ compared with that of CD3- and lymphokine (interleukin (IL)2)-activated killer (CD3-LAK) cells commonly used in immunotherapy were revealed.

Information related to the author
© 2012 The Pharmaceutical Society of Japan
Previous article Next article